Ex Vivo and In Vivo Administration of Fluorescent CNA35 Specifically Marks Cardiac Fibrosis

Sanne de Jong, Lars B. van Middendorp*, Robin H. A. Hermans, Jacques M. T. de Bakker, Marti F. A. Bierhuizen, Frits W. Prinzen, Harold V. M. van Rijen, Mario Losen, Marc A. Vos, Marc A. M. J. van Zandvoort

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Web of Science)


Cardiac fibrosis is a major hallmark of cardiac diseases. For evaluation of cardiac fibrosis, the development of highly specific and preferably noninvasive methods is desired. Our aim was to evaluate CNA35, a protein known to specifically bind to collagen, as a specific marker of cardiac fibrosis. Fluorescently labeled CNA35 was applied ex vivo on tissue sections of fibrotic rat, mouse, and canine myocardium. After quantification of CNA35, sections were examined with picrosirius red (PSR) and compared to CNA35. Furthermore, fluorescently labeled CNA35 was administered in vivo in mice. Hearts were isolated, and CNA35 labeling was examined in tissue sections. Serial sections were histologically examined with PSR. Ex vivo application of CNA35 showed specific binding to collagen and a high correlation with PSR (Pearson r = .86 for mice/rats and r = .98 for canine; both p,
Original languageEnglish
JournalMolecular Imaging
Publication statusPublished - Dec 2014

Cite this